Top news of the week: 01.03.2023.
AI, ChatGPT And The Future Of Drug Discovery: China Biotech CEO Podcast With Insilico's Co-CEO
<p>After securing US orphan designation for an artificial intelligence-assisted therapeutic, Insilico's co-CEO Feng Ren sits down for a wide-ranging interview in which he discusses why AI ...
5 advancements in rare disease research over the past year
Five recent advancements that have transformed research and boosted the scope for the development of novel therapies.
Notch Researchers Develop Improved Model for Predicting CAR-T Clinical Pharmacology and Response to Advance Next-Generation Product Design; Results Published in Nature Biotechnology
VANCOUVER, British Columbia, February 27, 2023— Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for ...
Moderna and Life Edit Therapeutics look to speed up gene editing therapies
Moderna and Life Edit Therapeutics have announced an R&D collaboration to discover and develop in vivo mRNA gene editing therapies.
From poetry to medicines: What ChatGPT and Drug Discovery Have in Common
As a curious AI enthusiast, I was captivated by the launch of ChatGPT by OpenAI last November. Like many others around the world, I am continuously amazed by its capabilities and ...
PackGene Breaks Ground on New cGMP Biomanufacturing Facility
PackGene works with customers to support gene therapy programs from early-stage R&D to IND-enabling studies.
Special Issue on Spatial Omics
Special Issue on Spatial Omics- Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in the ...
After US Woes, Akebia Celebrates EU Nod For Vafseo
<p>The US biotech is in the throes of an appeal to the FDA against the rejection of its HIF-PH inhibitor but regulators in the EU have looked more kindly on vadadustat, which will be sold ...